MedTrace Logo

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

NCT06006858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1284

Last updated 2023-11-18

No results posted yet for this study

Summary

This study is Post Authorization Safety Study (PASS) Phase IV of Moderna COVID-19 Primary Vaccine

Conditions

Interventions

BIOLOGICAL

Moderna COVID-19 Vaccine

Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.

Sponsors & Collaborators

  • National Advisory Immunization Committee Indonesia

    collaborator UNKNOWN

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Julitasari Sundoro, MD · National Advisory Immunization Committee

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06006858 on ClinicalTrials.gov